Microbiome changes during tuberculosis and antituberculous therapy

Clinical Microbiology Reviews

Volumn 29, Issue 4, 2016, Pages 915-926

  Hong, Bo Young ^a   Maulén, Nancy Paula ^b   Adami, Alexander J ^c   Granados, Hector ^d   Balcells, María Elvira ^e   Cervantes, Jorge ^d  

^a JACKSON LABORATORY   (United States)

^b Servicio de Psiquiatría Hospital Clínico Dr Félix Búlnes   (Chile)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^d Texas Tech University Health Sciences Center El Paso   (United States)

^e PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; TUBERCULOSTATIC AGENT;

ANTIBIOTIC THERAPY; ARTICLE; COMAMONAS; COMORBIDITY; DYSBIOSIS; HUMAN; IMMUNE RESPONSE; LUNG TUBERCULOSIS; METHYLOBACTERIUM; MICROBIAL COMMUNITY; MICROBIAL DIVERSITY; MICROBIOME; MYCOBACTERIUM TUBERCULOSIS; NEXT GENERATION SEQUENCING; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PYROSEQUENCING; RISK FACTOR; SPHINGOMONAS; SPUTUM ANALYSIS; TREATMENT OUTCOME; DRUG EFFECTS; MICROBIOLOGY; MICROFLORA; RESPIRATORY SYSTEM; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DYSBIOSIS; HUMANS; MICROBIOTA; RESPIRATORY SYSTEM; TUBERCULOSIS;

EID: 84986550110     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00096-15     Document Type: Article

References (108)

1. World Health Organization. 2013. Global tuberculosis report 2013. World Health Organization, Geneva, Switzerland
2. Jeon CY, Murray MB. 2008. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med 5:e152. http://dx.doi.org/10.1371/journal.pmed.0050152
3. Shuldiner J, Leventhal A, Chemtob D, Mor Z. 2016. Mortality after anti-tuberculosis treatment completion: results of long-term follow-up. Int J Tuberc Lung Dis 20:43–48. http://dx.doi.org/10.5588/ijtld.14.0427
4. Horne DJ, Royce SE, Gooze L, Narita M, Hopewell PC, Nahid P, Steingart KR. 2010. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect Dis 10:387–394. http://dx.doi.org/10.1016/S1473-3099(10)70071-2
5. Wu J, Liu W, He L, Huang F, Chen J, Cui P, Shen Y, Zhao J, Wang W, Zhang Y, Zhu M, Zhang W, Zhang Y. 2013. Sputum microbiota associated with new, recurrent and treatment failure tuberculosis. PLoS One 8:e83445. http://dx.doi.org/10.1371/journal.pone.0083445
6. NIH HMP Working Group, Peterson J, Garges S, Giovanni M, McInnes P, Wang L, Schloss JA, Bonazzi V, McEwen JE, Wetterstrand KA, Deal C, Baker CC, Di Francesco V, Howcroft TK, Karp RW, Lunsford RD, Wellington CR, Belachew T, Wright M, Giblin C, Davi H, Mills M, Salomon R, Mullins C, Akolkar B, Begg L, Davis C, Grandison L, Humble M, Khalsa J, Little AR, Peavy H, Pontzer C, Portnoy M, Sayre MH, Starke-Reed P, Zakhari S, Read J, Watson B, Guyer M. 2009. The NIH Human Microbiome Project. Genome Res 19:2317–2323. http://dx.doi.org/10.1101/gr.096651.109
7. Botero LE, Delgado-Serrano L, Cepeda ML, Bustos JR, Anzola JM, Del Portillo P, Robledo J, Zambrano MM. 2014. Respiratory tract clinical sample selection for microbiota analysis in patients with pulmonary tuberculosis. Microbiome 2:29. http://dx.doi.org/10.1186/2049-2618-2-29
8. Cheung MK, Lam WY, Fung WY, Law PT, Au CH, Nong W, Kam KM, Kwan HS, Tsui SK. 2013. Sputum microbiota in tuberculosis as revealed by 16S rRNA pyrosequencing. PLoS One 8:e54574. http://dx.doi.org/10.1371/journal.pone.0054574
9. Cui Z, Zhou Y, Li H, Zhang Y, Zhang S, Tang S, Guo X. 2012. Complex sputum microbial composition in patients with pulmonary tuberculosis. BMC Microbiol 12:276. http://dx.doi.org/10.1186/1471-2180-12-276
10. Human Microbiome Project Consortium. 2012. Structure, function and diversity of the healthy human microbiome. Nature 486:207–214. http://dx.doi.org/10.1038/nature11234
11. Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, Magris M, Hidalgo G, Baldassano RN, Anokhin AP, Heath AC, Warner B, Reeder J, Kuczynski J, Caporaso JG, Lozupone CA, Lauber C, Clemente JC, Knights D, Knight R, Gordon JI. 2012. Human gut microbiome viewed across age and geography. Nature 486: 222–227. http://dx.doi.org/10.1038/nature11053
12. Wade WG. 2013. The oral microbiome in health and disease. Pharmacol Res 69:137–143. http://dx.doi.org/10.1016/j.phrs.2012.11.006
13. Weiner J, III, Parida SK, Maertzdorf J, Black GF, Repsilber D, Telaar A, Mohney RP, Arndt-Sullivan C, Ganoza CA, Fae KC, Walzl G, Kaufmann SH. 2012. Biomarkers of inflammation, immunosuppression and stress with active disease are revealed by metabolomic profiling of tuberculosis patients. PLoS One 7:e40221. http://dx.doi.org/10.1371/journal.pone.0040221
14. Grice EA, Kong HH, Renaud G, Young AC, Bouffard GG, Blakesley RW, Wolfsberg TG, Turner ML, Segre JA. 2008. A diversity profile of the human skin microbiota. Genome Res 18:1043–1050. http://dx.doi.org/10.1101/gr.075549.107
15. Hilty M, Burke C, Pedro H, Cardenas P, Bush A, Bossley C, Davies J, Ervine A, Poulter L, Pachter L, Moffatt MF, Cookson WO. 2010. Disordered microbial communities in asthmatic airways. PLoS One 5:e8578. http://dx.doi.org/10.1371/journal.pone.0008578
16. Cox MJ, Cookson WO, Moffatt MF. 2013. Sequencing the human microbiome in health and disease. Hum Mol Genet 22:R88–R94. http://dx.doi.org/10.1093/hmg/ddt398
17. Marchesi JR, Ravel J. 2015. The vocabulary of microbiome research: a proposal. Microbiome 3:31. http://dx.doi.org/10.1186/s40168-015-0094-5
18. Kamada N, Chen GY, Inohara N, Nunez G. 2013. Control of pathogens and pathobionts by the gut microbiota. Nat Immunol 14:685–690. http://dx.doi.org/10.1038/ni.2608
19. Backhed F, Fraser CM, Ringel Y, Sanders ME, Sartor RB, Sherman PM, Versalovic J, Young V, Finlay BB. 2012. Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications. Cell Host Microbe 12:611–622. http://dx.doi.org/10.1016/j.chom.2012.10.012
20. Blaser MJ, Falkow S. 2009. What are the consequences of the disappearing human microbiota? Nat Rev Microbiol 7:887–894. http://dx.doi.org/10.1038/nrmicro2245
21. Chung H, Pamp SJ, Hill JA, Surana NK, Edelman SM, Troy EB, Reading NC, Villablanca EJ, Wang S, Mora JR, Umesaki Y, Mathis D, Benoist C, Relman DA, Kasper DL. 2012. Gut immune maturation depends on colonization with a host-specific microbiota. Cell 149:1578–1593. http://dx.doi.org/10.1016/j.cell.2012.04.037
22. Duan J, Chung H, Troy E, Kasper DL. 2010. Microbial colonization drives expansion of IL-1 receptor 1-expressing and IL-17-producing gamma/delta T cells. Cell Host Microbe 7:140–150. http://dx.doi.org/10.1016/j.chom.2010.01.005
23. Wingender G, Stepniak D, Krebs P, Lin L, McBride S, Wei B, Braun J, Mazmanian SK, Kronenberg M. 2012. Intestinal microbes affect phenotypes and functions of invariant natural killer T cells in mice. Gastroenterology 143:418–428. http://dx.doi.org/10.1053/j.gastro.2012.04.017
24. Lathrop SK, Bloom SM, Rao SM, Nutsch K, Lio CW, Santacruz N, Peterson DA, Stappenbeck TS, Hsieh CS. 2011. Peripheral education of the immune system by colonic commensal microbiota. Nature 478:250–254. http://dx.doi.org/10.1038/nature10434
25. Macpherson AJ, Uhr T. 2004. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science 303:1662–1665. http://dx.doi.org/10.1126/science.1091334
26. Zhang G, Chen R, Rudney JD. 2008. Streptococcus cristatus attenuates Fusobacterium nucleatum-induced interleukin-8 expression in oral epithelial cells. J Periodont Res 43:408–416. http://dx.doi.org/10.1111/j.1600-0765.2007.01057.x
27. Olszak T, An D, Zeissig S, Vera MP, Richter J, Franke A, Glickman JN, Siebert R, Baron RM, Kasper DL, Blumberg RS. 2012. Microbial exposure during early life has persistent effects on natural killer T cell function. Science 336:489–493. http://dx.doi.org/10.1126/science.1219328
28. Diehl GE, Longman RS, Zhang JX, Breart B, Galan C, Cuesta A, Schwab SR, Littman DR. 2013. Microbiota restricts trafficking of bacteria to mesenteric lymph nodes by CX(3)CR1(hi) cells. Nature 494: 116–120. http://dx.doi.org/10.1038/nature11809
29. Winglee K, Eloe-Fadrosh E, Gupta S, Guo H, Fraser C, Bishai W. 2014. Aerosol Mycobacterium tuberculosis infection causes rapid loss of diversity in gut microbiota. PLoS One 9:e97048. http://dx.doi.org/10.1371/journal.pone.0097048
30. Krishna P, Jain A, Bisen PS. 2016. Microbiome diversity in the sputum of patients with pulmonary tuberculosis. Eur J Clin Microbiol Infect Dis 35:1205–1210. http://dx.doi.org/10.1007/s10096-016-2654-4
31. Petersen C, Round JL. 2014. Defining dysbiosis and its influence on host immunity and disease. Cell Microbiol 16:1024–1033. http://dx.doi.org/10.1111/cmi.12308
32. Dickson RP, Erb-Downward JR, Huffnagle GB. 2014. Towards an ecology of the lung: new conceptual models of pulmonary microbiology and pneumonia pathogenesis. Lancet Respir Med 2:238–246. http://dx.doi.org/10.1016/S2213-2600(14)70028-1
33. Gollwitzer ES, Marsland BJ. 2014. Microbiota abnormalities in inflammatory airway diseases - potential for therapy. Pharmacol Ther 141:32–39. http://dx.doi.org/10.1016/j.pharmthera.2013.08.002
34. Tyler AD, Smith MI, Silverberg MS. 2014. Analyzing the human microbiome: a “how to” guide for physicians. Am J Gastroenterol 109:983–993. http://dx.doi.org/10.1038/ajg.2014.73
35. Ege MJ, Mayer M, Normand AC, Genuneit J, Cookson WO, Braun-Fahrlander C, Heederik D, Piarroux R, von Mutius E, GABRIELA Transregio 22 Study Group. 2011. Exposure to environmental microorganisms and childhood asthma. N Engl J Med 364:701–709. http://dx.doi.org/10.1056/NEJMoa1007302
36. Saraswati S, Sitaraman R. 2014. Aging and the human gut microbiotafrom correlation to causality. Front Microbiol 5:764. http://dx.doi.org/10.3389/fmicb.2014.00764
37. Nielsen DS, Krych L, Buschard K, Hansen CH, Hansen AK. 2014. Beyond genetics. Influence of dietary factors and gut microbiota on type 1 diabetes. FEBS Lett 588:4234–4243. http://dx.doi.org/10.1016/j.febslet.2014.04.010
38. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D, Peng Y, Zhang D, Jie Z, Wu W, Qin Y, Xue W, Li J, Han L, Lu D, Wu P, Dai Y, Sun X, Li Z, Tang A, Zhong S, Li X, Chen W, Xu R, Wang M, Feng Q, Gong M, Yu J, Zhang Y, Zhang M, Hansen T, Sanchez G, Raes J, Falony G, Okuda S, Almeida M, LeChatelier E, Renault P, Pons N, Batto JM, Zhang Z, Chen H, Yang R, Zheng W, Yang H, Wang J, Ehrlich SD, Nielsen R, Pedersen O, Kristiansen K, Wang J. 2012. A metagenomewide association study of gut microbiota in type 2 diabetes. Nature 490:55–60. http://dx.doi.org/10.1038/nature11450
39. Mejia-Leon ME, Petrosino JF, Ajami NJ, Dominguez-Bello MG, de la Barca AM. 2014. Fecal microbiota imbalance in Mexican children with type 1 diabetes. Sci Rep 4:3814. http://dx.doi.org/10.1038/srep03814
40. Subramanian S, Huq S, Yatsunenko T, Haque R, Mahfuz M, Alam MA, Benezra A, DeStefano J, Meier MF, Muegge BD, Barratt MJ, VanArendonk LG, Zhang Q, Province MA, Petri WA, Jr, Ahmed T, Gordon JI. 2014. Persistent gut microbiota immaturity in malnourished Bangladeshi children. Nature 510:417–421. http://dx.doi.org/10.1038/nature13421
41. Monira S, Nakamura S, Gotoh K, Izutsu K, Watanabe H, Alam NH, Endtz HP, Cravioto A, Ali SI, Nakaya T, Horii T, Iida T, Alam M. 2011. Gut microbiota of healthy and malnourished children in Bangladesh. Front Microbiol 2:228. http://dx.doi.org/10.3389/fmicb.2011.00228
42. Restrepo BI, Schlesinger LS. 2014. Impact of diabetes on the natural history of tuberculosis. Diabetes Res Clin Pract 106:191–199. http://dx.doi.org/10.1016/j.diabres.2014.06.011
43. Rajagopalan S. 2001. Tuberculosis and aging: a global health problem. Clin Infect Dis 33:1034–1039. http://dx.doi.org/10.1086/322671
44. Swaminathan S, Padmapriyadarsini C. 2014. Undernutrition and tuberculosis: strongly linked, but ignored. Natl Med J India 27:125–127
45. Upadhyay R, Singh A. 2012. Tuberculosis in liver cirrhosis. Med Update 22:476–478
46. Mori T, Leung CC. 2010. Tuberculosis in the global aging population. Infect Dis Clin North Am 24:751–768. http://dx.doi.org/10.1016/j.idc.2010.04.011
47. Dickson RP, Huffnagle GB. 2015. The lung microbiome: new principles for respiratory bacteriology in health and disease. PLoS Pathog 11: e1004923. http://dx.doi.org/10.1371/journal.ppat.1004923
48. Perry S, de Jong BC, Solnick JV, de la Luz Sanchez M, Yang S, Lin PL, Hansen LM, Talat N, Hill PC, Hussain R, Adegbola RA, Flynn J, Canfield D, Parsonnet J. 2010. Infection with Helicobacter pylori is associated with protection against tuberculosis. PLoS One 5:e8804. http://dx.doi.org/10.1371/journal.pone.0008804
49. Schuijt TJ, Lankelma JM, Scicluna BP, de Sousa e Melo F, Roelofs JJ, de Boer JD, Hoogendijk AJ, de Beer R, de Vos A, Belzer C, de Vos WM, van der Poll T, Wiersinga WJ. 2016. The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia. Gut 65:575–583. http://dx.doi.org/10.1136/gutjnl-2015-309728
50. Samuelson DR, Welsh DA, Shellito JE. 2015. Regulation of lung immunity and host defense by the intestinal microbiota. Front Microbiol 6:1085. http://dx.doi.org/10.3389/fmicb.2015.01085
51. Tsay TB, Yang MC, Chen PH, Hsu CM, Chen LW. 2011. Gut flora enhance bacterial clearance in lung through Toll-like receptors 4. J Biomed Sci 18:68. http://dx.doi.org/10.1186/1423-0127-18-68
52. Russell SL, Gold MJ, Reynolds LA, Willing BP, Dimitriu P, Thorson L, Redpath SA, Perona-Wright G, Blanchet M-R, Mohn WW, Finlay BB, McNagny KM. 2015. Perinatal antibiotic-induced shifts in gut microbiota have differential effects on inflammatory lung diseases. J Allergy Clin Immunol 135:100–109. http://dx.doi.org/10.1016/j.jaci.2014.06.027
53. Rappuoli R, Aderem A. 2011. A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 473:463–469. http://dx.doi.org/10.1038/nature10124
54. Yoo JW, Jo KW, Kang BH, Kim MY, Yoo B, Lee CK, Kim YG, Yang SK, Byeon JS, Kim KJ, Ye BD, Shim TS. 2014. Mycobacterial diseases developed during anti-tumour necrosis factor-alpha therapy. Eur Respir J 44:1289–1295. http://dx.doi.org/10.1183/09031936.00063514
55. Huang HY, Tsai YS, Lee JJ, Chiang MC, Chen YH, Chiang CY, Lin NT, Tsai PJ. 2010. Mixed infection with Beijing and non-Beijing strains and drug resistance pattern of Mycobacterium tuberculosis. J Clin Microbiol 48:4474–4480. http://dx.doi.org/10.1128/JCM.00930-10
56. Khan Z, Miller A, Bachan M, Donath J. 2010. Mycobacterium avium complex (MAC) lung disease in two inner city community hospitals: recognition, prevalence, co-infection with Mycobacterium tuberculosis (MTB) and pulmonary function (PF) improvements after treatment. Open Respir Med J 4:76–81. http://dx.doi.org/10.2174 /1874306401004010076
57. Ravel J, Brotman R, Gajer P, Ma B, Nandy M, Fadrosh D, Sakamoto J, Koenig S, Fu L, Zhou X, Hickey R, Schwebke J, Forney L. 2013. Daily temporal dynamics of vaginal microbiota before, during and after episodes of bacterial vaginosis. Microbiome 1:29. http://dx.doi.org/10.1186/2049-2618-1-29
58. Peterson SN, Snesrud E, Liu J, Ong AC, Kilian M, Schork NJ, Bretz W. 2013. The dental plaque microbiome in health and disease. PLoS One 8:e58487. http://dx.doi.org/10.1371/journal.pone.0058487
59. Proal AD, Albert PJ, Marshall T. 2009. Autoimmune disease in the era of the metagenome. Autoimmun Rev 8:677–681. http://dx.doi.org/10.1016/j.autrev.2009.02.016
60. Zhou Y, Lin F, Cui Z, Zhang X, Hu C, Shen T, Chen C, Guo X. 2015. Correlation between either Cupriavidus or Porphyromonas and primary pulmonary tuberculosis found by analysing the microbiota in patients’ bronchoalveolar lavage fluid. PLoS One 10:e0124194. http://dx.doi.org/10.1371/journal.pone.0124194
61. Bassis CM, Erb-Downward JR, Dickson RP, Freeman CM, Schmidt TM, Young VB, Beck JM, Curtis JL, Huffnagle GB. 2015. Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals. mBio 6:e00037-15. http://dx.doi.org/10.1128/mBio.00037-15
62. Marsland BJ, Gollwitzer ES. 2014. Host-microorganism interactions in lung diseases. Nat Rev Immunol 14:827–835. http://dx.doi.org/10.1038/nri3769
63. Sansonetti PJ. 2013. Microbiota and the immune system, an amazing mutualism forged by co-evolution. Semin Immunol 25:321–322. http://dx.doi.org/10.1016/j.smim.2013.10.003
64. Lozupone CA, Stombaugh J, Gonzalez A, Ackermann G, Wendel D, Vazquez-Baeza Y, Jansson JK, Gordon JI, Knight R. 2013. Metaanalyses of studies of the human microbiota. Genome Res 23:1704–1714. http://dx.doi.org/10.1101/gr.151803.112
65. Ding T, Schloss PD. 2014. Dynamics and associations of microbial community types across the human body. Nature 509:357–360. http://dx.doi.org/10.1038/nature13178
66. Adami A, Cervantes J. 2015. The microbiome at the pulmonary alveolar niche and its role in Mycobacterium tuberculosis infection. Tuberculosis 95:651–658. http://dx.doi.org/10.1016/j.tube.2015.07.004
67. Goddard AF, Staudinger BJ, Dowd SE, Joshi-Datar A, Wolcott RD, Aitken ML, Fligner CL, Singh PK. 2012. Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upper-airway specimens can misrepresent lung microbiota. Proc Natl Acad Sci U S A 109: 13769–13774. http://dx.doi.org/10.1073/pnas.1107435109
68. Cabrera-Rubio R, Garcia-Núñez M, Setó L, Antó JM, Moya A, Monsó E, Mira A. 2012. Microbiome diversity in the bronchial tracts of patients with chronic obstructive pulmonary disease. J Clin Microbiol 50:3562–3568. http://dx.doi.org/10.1128/JCM.00767-12
69. Yuan S, Cohen DB, Ravel J, Abdo Z, Forney LJ. 2012. Evaluation of methods for the extraction and purification of DNA from the human microbiome. PLoS One 7:e33865. http://dx.doi.org/10.1371/journal.pone.0033865
70. Fredricks DN, Smith C, Meier A. 2005. Comparison of six DNA extraction methods for recovery of fungal DNA as assessed by quantitative PCR. J Clin Microbiol 43:5122–5128. http://dx.doi.org/10.1128/JCM.43.10.5122-5128.2005
71. Loman NJ, Misra RV, Dallman TJ, Constantinidou C, Gharbia SE, Wain J, Pallen MJ. 2012. Performance comparison of benchtop highthroughput sequencing platforms. Nat Biotechnol 30:434–439. http://dx.doi.org/10.1038/nbt.2198
72. Huse SM, Ye Y, Zhou Y, Fodor AA. 2012. A core human microbiome as viewed through 16S rRNA sequence clusters. PLoS One 7:e34242. http://dx.doi.org/10.1371/journal.pone.0034242
73. Chakravorty S, Helb D, Burday M, Connell N, Alland D. 2007. A detailed analysis of 16S ribosomal RNA gene segments for the diagnosis of pathogenic bacteria. J Microbiol Methods 69:330–339. http://dx.doi.org/10.1016/j.mimet.2007.02.005
74. Nelson MC, Morrison HG, Benjamino J, Grim SL, Graf J. 2014. Analysis, optimization and verification of Illumina-generated 16S rRNA gene amplicon surveys. PLoS One 9:e94249. http://dx.doi.org/10.1371/journal.pone.0094249
75. Hamady M, Knight R. 2009. Microbial community profiling for human microbiome projects: tools, techniques, and challenges. Genome Res 19: 1141–1152. http://dx.doi.org/10.1101/gr.085464.108
76. Franzosa EA, Hsu T, Sirota-Madi A, Shafquat A, Abu-Ali G, Morgan XC, Huttenhower C. 2015. Sequencing and beyond: integrating molecular ‘omics’ for microbial community profiling. Nat Rev Microbiol 13: 360–372. http://dx.doi.org/10.1038/nrmicro3451
77. Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, Reyes JA, Shah SA, LeLeiko N, Snapper SB, Bousvaros A, Korzenik J, Sands BE, Xavier RJ, Huttenhower C. 2012. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 13:R79. http://dx.doi.org/10.1186/gb-2012-13-9-r79
78. Page RD. 2013. BioNames: linking taxonomy, texts, and trees. PeerJ 1:e190. http://dx.doi.org/10.7717/peerj.190
79. Schoch CL, Robbertse B, Robert V, Vu D, Cardinali G, Irinyi L, Meyer W, Nilsson RH, Hughes K, Miller AN, Kirk PM, Abarenkov K, Aime MC, Ariyawansa HA, Bidartondo M, Boekhout T, Buyck B, Cai Q, Chen J, Crespo A, Crous PW, Damm U, De Beer ZW, Dentinger BT, Hong, Divakar PK, Duenas M, Feau N, Fliegerova K, Garcia MA, Ge ZW, Griffith GW, Groenewald JZ, Groenewald M, Grube M, Gryzenhout M, Gueidan C, Guo L, Hambleton S, Hamelin R, Hansen K, Hofstetter V, Hong SB, Houbraken J, Hyde KD, Inderbitzin P, Johnston PR, Karunarathna SC, Koljalg U, Kovacs GM, Kraichak E, Krizsan K, et al. 2014. Finding needles in haystacks: linking scientific names, reference specimens and molecular data for Fungi. Database (Oxford) 2014:pii: bau061. http://dx.doi.org/10.1093/database/bau061
80. Kim YG, Udayanga KG, Totsuka N, Weinberg JB, Nunez G, Shibuya A. 2014. Gut dysbiosis promotes M2 macrophage polarization and allergic airway inflammation via fungi-induced PGE(2). Cell Host Microbe 15:95–102. http://dx.doi.org/10.1016/j.chom.2013.12.010
81. Pfeiffer JK, Virgin HW. 2016. Viral immunity. Transkingdom control of viral infection and immunity in the mammalian intestine. Science 351: pii:aad5872. http://dx.doi.org/10.1126/science.aad5872
82. Weinstock GM. 2012. Genomic approaches to studying the human microbiota. Nature 489:250–256. http://dx.doi.org/10.1038/nature11553
83. Edgar RC. 2013. UPARSE: highly accurate OTU sequences from microbial amplicon reads. Nat Methods 10:996–998. http://dx.doi.org/10.1038/nmeth.2604
84. Gaspar JM, Thomas WK. 2013. Assessing the consequences of denoising marker-based metagenomic data. PLoS One 8:e60458. http://dx.doi.org/10.1371/journal.pone.0060458
85. D’Argenio V, Casaburi G, Precone V, Salvatore F. 2014. Comparative metagenomic analysis of human gut microbiome composition using two different bioinformatic pipelines. Biomed Res Int 2014:325340. http://dx.doi.org/10.1155/2014/325340
86. Hildebrand F, Tadeo R, Voigt A, Bork P, Raes J. 2014. LotuS: an efficient and user-friendly OTU processing pipeline. Microbiome 2:30. http://dx.doi.org/10.1186/2049-2618-2-30
87. Fosso B, Santamaria M, Marzano M, Alonso-Alemany D, Valiente G, Donvito G, Monaco A, Notarangelo P, Pesole G. 2015. BioMaS: a modular pipeline for Bioinformatic analysis of Metagenomic AmpliconS. BMC Bioinformatics 16:203. http://dx.doi.org/10.1186/s12859-015-0595-z
88. Majaneva M, Hyytiainen K, Varvio SL, Nagai S, Blomster J. 2015. Bioinformatic amplicon read processing strategies strongly affect eukaryotic diversity and the taxonomic composition of communities. PLoS One 10:e0130035. http://dx.doi.org/10.1371/journal.pone.0130035
89. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Pena AG, Goodrich JK, Gordon JI, Huttley GA, Kelley ST, Knights D, Koenig JE, Ley RE, Lozupone CA, McDonald D, Muegge BD, Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann J, Yatsunenko T, Zaneveld J, Knight R. 2010. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 7:335–336. http://dx.doi.org/10.1038/nmeth.f.303
90. McDonald D, Price MN, Goodrich J, Nawrocki EP, DeSantis TZ, Probst A, Andersen GL, Knight R, Hugenholtz P. 2012. An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. ISME J 6:610–618. http://dx.doi.org/10.1038/ismej.2011.139
91. Robinson CJ, Young VB. 2010. Antibiotic administration alters the community structure of the gastrointestinal microbiota. Gut Microbes 1:279–284. http://dx.doi.org/10.4161/gmic.1.4.12614
92. Jernberg C, Lofmark S, Edlund C, Jansson JK. 2010. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology 156:3216–3223. http://dx.doi.org/10.1099/mic.0.040618-0
93. Dubourg G, Lagier JC, Armougom F, Robert C, Hamad I, Brouqui P, Raoult D. 2013. The gut microbiota of a patient with resistant tuberculosis is more comprehensively studied by culturomics than by metagenomics. Eur J Clin Microbiol Infect Dis 32:637–645. http://dx.doi.org/10.1007/s10096-012-1787-3
94. Jakobsson HE, Jernberg C, Andersson AF, Sjolund-Karlsson M, Jansson JK, Engstrand L. 2010. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One 5:e9836. http://dx.doi.org/10.1371/journal.pone.0009836
95. Dethlefsen L, Relman DA. 2011. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A 108(Suppl 1):4554–4561. http://dx.doi.org/10.1073/pnas.1000087107
96. Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, Darst SA. 2001. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 104:901–912.http://dx.doi.org/10.1016/S0092-8674(01)00286-0
97. Feller M, Huwiler K, Stephan R, Altpeter E, Shang A, Furrer H, Pfyffer GE, Jemmi T, Baumgartner A, Egger M. 2007. Mycobacterium avium subspecies paratuberculosis and Crohn’s disease: a systematic review and meta-analysis. Lancet Infect Dis 7:607–613. http://dx.doi.org/10.1016/S1473-3099(07)70211-6
98. Ren Z, Turton J, Borody T, Pang G, Clancy R. 2008. Selective Th2 pattern of cytokine secretion in Mycobacterium avium subsp. paratuberculosis infected Crohn’s disease. J Gastroenterol Hepatol 23:310–314. http://dx.doi.org/10.1111/j.1440-1746.2007.04865.x
99. Pierce ES. 2009. Where are all the Mycobacterium avium subspecies paratuberculosis in patients with Crohn’s disease? PLoS Pathog 5:e1000234. http://dx.doi.org/10.1371/journal.ppat.1000234
100. Prantera C, Bothamley G, Levenstein S, Mangiarotti R, Argentieri R. 1989. Crohn’s disease and mycobacteria: two cases of Crohn’s disease with high anti-mycobacterial antibody levels cured by dapsone therapy. Biomed Pharmacother 43:295–299. http://dx.doi.org/10.1016/0753-3322(89)90011-5
101. Selby W, Pavli P, Crotty B, Florin T, Radford-Smith G, Gibson P, Mitchell B, Connell W, Read R, Merrett M, Ee H, Hetzel D, Antibiotics in Crohn’s Disease Study Group. 2007. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn’s disease. Gastroenterology 132:2313–2319. http://dx.doi.org/10.1053/j.gastro.2007.03.031
102. Schoenfeld P, Pimentel M, Chang L, Lembo A, Chey WD, Yu J, Paterson C, Bortey E, Forbes WP. 2014. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebocontrolled trials. Aliment Pharmacol Ther 39:1161–1168. http://dx.doi.org/10.1111/apt.12735
103. Oldfield EC, IV, Oldfield EC, III, Johnson DA. 2014. Clinical update for the diagnosis and treatment of Clostridium difficile infection. World J Gastrointest Pharmacol Ther 5:1–26. http://dx.doi.org/10.4292/wjgpt.v5.i1.1
104. Gao J, Gillilland MG, III, Owyang C. 2014. Rifaximin, gut microbes and mucosal inflammation: unraveling a complex relationship. Gut Microbes 5:571–575. http://dx.doi.org/10.4161/gmic.32130
105. Yew WW, Leung CC. 2006. Antituberculosis drugs and hepatotoxicity. Respirology 11:699–707. http://dx.doi.org/10.1111/j.1440-1843.2006.00941.x
106. Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. 2012. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother 67:742–748. http://dx.doi.org/10.1093/jac/dkr508
107. Brown E, Talbot GH, Axelrod P, Provencher M, Hoegg C. 1990. Risk factors for Clostridium difficile toxin-associated diarrhea. Infect Control Hosp Epidemiol 11:283–290. http://dx.doi.org/10.2307/30145487
108. Ensminger P, Counter F, Thomas L, Lubbehusen P. 1982. Susceptibility, resistance development, and synergy of antimicrobial combinations against Clostridium difficile. Curr Microbiol 7:59–62. http://dx.doi.org/10.1007/BF01570982.